Professor Yong-Jie Lu obtained his medical degree in 1989 and PhD in 1995. His work aims at identification of genetic alterations and genetic mechanisms in cancer development, progression and therapeutic response. He established his research team in 2003 at Barts Cancer Institute, Queen Mary University of London, working on male urological cancer, in particular prostate cancer. He is a long-term member of prostate cancer International Cancer Genome Consortium and prostate cancer genetic risk study international consortium. In recent years, his research moved into prostate cancer liquid biopsy, in particular circulating biomarker studies, aiming to translate them into cancer diagnosis, prognosis and therapeutic stratification. He is an executive board member of the European Liquid Biopsy Society and co-chair of its Circulating Tumour Cell Working Group. He also developed a strong interest in cancer immunology. Prof. Lu published 200 peer reviewed papers, in journals including Lancet, Nature Genetics, PNAS and Nature Reviews Clinical Oncology. His research findings have been highlighted multiple times in dozens of national and international media, including BBC TV news and CCTV News. He is on the editorial board of a few scientific journals, such as Drug Resistance Update and American Journal of Cancer Research and a grant reviewer/selection panel member of many funding bodies.
Queen Mary University of London
London, City of London, UK
Barts Cancer Institute
Senior Scientist or Principal Investigator
Queen Mary University of London, London, UK
01 Jun 2003 - present
Senior Scientist or Principal Investigator
The Institute of Cancer Research, London, UK
01 Oct 2001 - 01 Jun 2023
Post Doctoral Researcher
The Institute of Cancer Research, London, UK
01 Oct 1995 - 01 Sep 2001